The Cancer Bioinformatics group is exploring molecular determinants at the primary tumour site and in the draining lymph nodes, from complex data sets derived from clinically annotated samples and model systems, mainly in triple-negative breast cancers.
We consider transcriptional and structural copy number alterations pathognomonic for defects in DNA damage repair mechanisms, histological changes reflective of local and systemic immune responses, a patient’s resident microbial communities and how the sum of these individual components influence treatment response and disease progression.
Our Partners
Group lead
Professor